Clinical Trial Update: Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating circulating tumor DNA-guided boost therapy for early triple-negative breast cancer patients with residual disease after neoadj…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING